对蛋白转化酶子素/素9型抑制剂以及过敏和过敏反应的不成比例分析
Foteini Dermiki-Gkana1, Christopher A Gravel2,3,4,5, Christos Kontogiorgis6
1Laboratory of Hygiene and Environmental Protection, Department of Medicine, Democritus University of Thrace, Campus (Dragana), Alexandroupolis, Greece.
Scientific reports
|November 20, 2025
概括
这项研究总体上没有发现PCSK9抑制剂增加过敏或过敏反应的风险. 虽然alirocumab显示出轻微的关联,但进一步的分析表明它不是PCSK9抑制剂的化合物特异信号.
科学领域:
- 药物监督 药物监督 药物监督
- 心血管药理学心血管药理学
- 药品安全 药品安全
背景情况:
- 病例报告表明,蛋白转化酶亚素/素9型 (PCSK9) 抑制剂与严重过敏反应之间存在联系.
- 了解PCSK9抑制剂在过敏性方面的安全性,对于临床实践至关重要.
研究的目的:
- 评估PCSK9抑制剂报告与过敏或过敏反应之间的关联,使用大型药监数据库.
- 为了调查潜在的化合物特异信号对阿利罗库马布和evolocumab.
主要方法:
- 从2015年到2023年对美国食品和药物管理局不良事件报告系统 (FAERS) 数据库的分析.
- 不成比例指标的计算,包括报告几率比率 (ROR) 和信息组件 (IC).
- 进行了敏感性分析,调整了人口统计数据,使用他类药物作为比较剂,以及不同的结果定义.
主要成果:
- 没有观察到PCSK9抑制剂总体或evolocumab与过敏或过敏反应之间的关联.
- 对阿利罗马布和过敏症和过敏反应的潜在关联被注意到,但在分析中发现的结果不一致.
- 敏感性分析支持PCSK9抑制剂和evolocumab缺乏关联,而alirocumab的结果是不确定的.
结论:
- 该研究没有确定PCSK9抑制剂作为一种类的过敏或过敏反应不成比例报告的信号.
- 与alirocumab相关的研究结果的不一致性表明,观察到的关联可能不代表真正的化合物特定的安全信号.
相关概念视频
Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Hypersensitivities
7.2K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
7.2K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
298
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
298
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
615
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
615
Desensitization and Tachyphylaxis
3.0K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.0K
Cross-reactivity
32.8K
Overview
32.8K


